Remove 2020 Remove FDA Remove Immunization
article thumbnail

The top 5 pharma M&A deals of 2020

pharmaphorum

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

article thumbnail

Santhera seeks speedy FDA review of Duchenne drug vamorolone

pharmaphorum

The Swiss biotech is seeking a priority review for vamorolone, which was licensed from US biotech ReveraGen BioPharma in 2020 after Santhera its former DMD therapy candidate idebenone failed clinical testing and was abandoned. Its lead drug has already claimed fast track and rare paediatric disease designations from the FDA.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

4 vitamins for post-COVID fatigue

The Checkup by Singlecare

A 2022 study found that both B12 and B5 had protective effects against COVID infection, while a 2020 study found that vitamin B12 (when combined with vitamin D and magnesium) improved outcomes for elderly patients hospitalized with COVID-19. Vitamin C: Vitamin C is well known for its positive effects on the immune system.

article thumbnail

7 health benefits of raspberry leaf tea

The Checkup by Singlecare

Antioxidants are often associated with a healthy immune system, but they may also stave off disease by protecting cells from damage caused by free radicals. In a 2020 study , ellagic acid was shown to inhibit lung cancer cell proliferation and tumor growth. Does raspberry leaf interfere with medications?

article thumbnail

Lava fires up a $700m cancer licensing deal with Seagen

pharmaphorum

Seagen’s deal is another endorsement of Lava’s Gammabody platform, which creates drug candidates that target immune cells known as gamma delta or V?9V?2 It comes after Johnson & Johnson’s Janssen Biotech division signed up to access the bispecific antibody technology in 2020, without revealing any financial details.

article thumbnail

Re-engineering proteins to develop novel immunotherapies

European Pharmaceutical Review

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

article thumbnail

US FDA approves Kamada’s application to manufacture Cytogam

Pharmaceutical Technology

The US Food and Drug Administration (FDA) approved Kamada’s application to manufacture Cytogam (cytomegalovirus immune globulin intravenous [human]) at its facility located in Beit Kama, Israel. It is claimed to be the only immunoglobulin (IgG) product to receive FDA approval for this indication.

FDA 52